posting velocity //
Based on 0 events over 90 days. Green days had more opens than closes, red vice-versa. The dark line is the 7-day rolling average.
Posting timing (day/hour) is available only when there are at least 5 jobs with a real publish stamp spread across 3 distinct days. This company's source doesn't expose post times, or there isn't enough data yet — showing what we know for sure: how many jobs are open, in which domains, and at which seniority levels.
news feed
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOWnJ6bVlyaDU5eEV3NkhwUDJaZXhjWVBxQW1ieF9YaGhBMzU0cXFXeDBNRHJ3UjVhQ0o3OTVDaHFJU2h1SkNjMEs1MnJaaEJ1Mko5dzh0NUoyTWVaUDFsaTJJZktlamdqSUJObV9aem9IUmtSeU8ydjVPMUM5S0pueGswbDNmbV9FMzhoV3VVcUE5amZNeDdCTU5ocEZwUXg3RnZIQmZScnFuQlFxdFZsYXl4ZS1scXo0aXhORGlCb2xZTzJnQjdJZG4zN05DZw?oc=5" target="_blank">TARX IPO News - Israel-based ocular disease biotech Tarsier Pharma sets terms for $45 million US IPO</a> <font color="#6f6f6f">renaissancecapital.com</font>
May 18, 2026
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQRmxfdVJ2cU5QYnBUa3EtcFVybzJ3M2JmWUtKVjNmVGV2aWs0WW4xZVhRcVpOYklWU1ZXX1RKOVRKcGhmSlFnVmUxX0o4MDk4NzF2VFYyZ0JyeXNPNGxQTDR4dkFtRkRDc1FKR09sbHdwSTRxZ1lFOGo0MHhxTFctam1ncHRwYVZMenRXZnYwTnpKamtHWEhKMlg4Y1Q0dTFSNmtfSXlqekdkVHpXeFdCeDMwSXBodno0Q1JHUXhpbjl2SVFVbVZNX3kwQUsydw?oc=5" target="_blank">TARX IPO News - Israel-based Phase 3 ocular diseases biotech Tarsier Pharma files for a $35 million US IPO</a> <font color="#6f6f6f">renaissancecapital.com</font>
Apr 21, 2026
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOdWZsMEZWZDhVM1F0Z0pPbDF6SmQ4ZVBjT1QxQTdWWHpxR250SFowcjZaeXNCc0paUExuM0tLMVo2blBibUNsOEhybGRmZm1MYUEzWkZlMWNsVkxOem9sellRRU1ta3VDSlNxLUFyRWhNRlJPc1B4eGxSR0NkSmFFQ0JsRm55NWd1dEFpY0VRMVZUb3B4d2o2R3MzeVpERG1QMTVzaWFPWVJKY3g2bE9ucXVQSW1IQ1dPbDNoYUFZSWxoWXZ6Rnp3TV9aY1NUdw?oc=5" target="_blank">Israel-listed cell therapy biotech Bonus Biogroup increases shares offered by 25% ahead of $19 million US IPO</a> <font color="#6f6f6f">renaissancecapital.com</font>
Mar 31, 2026
<p>The Israel Innovation Authority (IIA) has approved a second year of funding for a joint R&D project to develop CRISPR gene-editing technology for crustaceans that will improve key traits such as growth rate, disease resistance and environmental adaptation. The joint project by sustainable aquaculture company Watershed AC, computational biotech firm Evogene and Ben-Gurion University of […]</p> <p>The post <a href="https://nocamels.com/2024/10/iia-funds-further-israeli-rd-into-crustacean-gene-modification/">IIA Funds Further Israeli R&D Into Crustacean Gene Modification</a> appeared first on <a href="https://nocamels.com">NoCamels</a>.</p>
Oct 9, 2024